Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver Disease
2024

Risks of Adverse Events in Patients with Atrial Fibrillation and Fatty Liver Disease

Sample size: 413650 publication 10 minutes Evidence: high

Author Information

Author(s): Tommaso Bucci, Katarzyna Nabrdalik, Francesco Baratta, Daniele Pastori, Pasquale Pignatelli, Theresa Hydes, Uazman Alam, Francesco Violi, Gregory Y H Lip

Primary Institution: Liverpool Centre for Cardiovascular Science at University of Liverpool

Hypothesis

What is the 1-year risk of all-cause death, thromboembolic events, and bleeding in patients with atrial fibrillation and nonalcoholic fatty liver disease?

Conclusion

Patients with atrial fibrillation and nonalcoholic fatty liver disease have a higher risk of adverse events over one year, especially if they also have cirrhosis or thrombocytopenia.

Supporting Evidence

  • NAFLD was associated with a higher risk of composite cardiovascular and hemorrhagic outcomes.
  • Patients with AF-NAFLD showed a higher prevalence of obesity, diabetes, and chronic kidney disease.
  • NOACs were associated with a better effectiveness and safety profile compared to warfarin.

Takeaway

People with heart problems and fatty liver disease are more likely to have serious health issues, especially if their liver is really sick.

Methodology

This was a retrospective study using a health research network to analyze patients with atrial fibrillation on anticoagulation, comparing those with and without nonalcoholic fatty liver disease.

Potential Biases

Potential underestimation of risks due to reliance on administrative data and possible selection bias.

Limitations

The study relies on ICD-10-CM codes for diagnosis, which may not capture all cases accurately, and it cannot assess liver fibrosis severity.

Participant Demographics

The study included 22,636 patients with AF-NAFLD (mean age 69 years, 46.7% females) and 391,014 patients with AF without liver disease (mean age 72 years, 42.7% females).

Statistical Information

P-Value

HR, 1.54; 95% CI, 1.47-1.61

Confidence Interval

95% CI, 1.47-1.61

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1210/clinem/dgae394

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication